261 related articles for article (PubMed ID: 23305851)
1. Resolution of the interaction mechanisms and characteristics of non-nucleoside inhibitors of hepatitis C virus polymerase.
Winquist J; Abdurakhmanov E; Baraznenok V; Henderson I; Vrang L; Danielson UH
Antiviral Res; 2013 Mar; 97(3):356-68. PubMed ID: 23305851
[TBL] [Abstract][Full Text] [Related]
2. Characterization of interactions between hepatitis C virus NS5B polymerase, annexin A2 and RNA - effects on NS5B catalysis and allosteric inhibition.
Solbak SMØ; Abdurakhmanov E; Vedeler A; Danielson UH
Virol J; 2017 Dec; 14(1):236. PubMed ID: 29228983
[TBL] [Abstract][Full Text] [Related]
3. NMR reveals the intrinsically disordered domain 2 of NS5A protein as an allosteric regulator of the hepatitis C virus RNA polymerase NS5B.
Bessa LM; Launay H; Dujardin M; Cantrelle FX; Lippens G; Landrieu I; Schneider R; Hanoulle X
J Biol Chem; 2017 Nov; 292(44):18024-18043. PubMed ID: 28912275
[TBL] [Abstract][Full Text] [Related]
4. Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors.
Elhefnawi M; ElGamacy M; Fares M
BMC Bioinformatics; 2012; 13 Suppl 17(Suppl 17):S5. PubMed ID: 23282180
[TBL] [Abstract][Full Text] [Related]
5. Current perspective of HCV NS5B inhibitors: a review.
Patil VM; Gupta SP; Samanta S; Masand N
Curr Med Chem; 2011; 18(36):5564-97. PubMed ID: 22172066
[TBL] [Abstract][Full Text] [Related]
6. Biophysical Mode-of-Action and Selectivity Analysis of Allosteric Inhibitors of Hepatitis C Virus (HCV) Polymerase.
Abdurakhmanov E; Øie Solbak S; Danielson UH
Viruses; 2017 Jun; 9(6):. PubMed ID: 28621755
[TBL] [Abstract][Full Text] [Related]
7. Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections.
Beaulieu PL
Curr Opin Investig Drugs; 2007 Aug; 8(8):614-34. PubMed ID: 17668364
[TBL] [Abstract][Full Text] [Related]
8. Dual Allosteric Inhibitors Jointly Modulate Protein Structure and Dynamics in the Hepatitis C Virus Polymerase.
Brown JA; Thorpe IF
Biochemistry; 2015 Jul; 54(26):4131-41. PubMed ID: 26066778
[TBL] [Abstract][Full Text] [Related]
9. Current race in the development of DAAs (direct-acting antivirals) against HCV.
De Clercq E
Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613
[TBL] [Abstract][Full Text] [Related]
10. Quinolones as HCV NS5B polymerase inhibitors.
Kumar DV; Rai R; Brameld KA; Somoza JR; Rajagopalan R; Janc JW; Xia YM; Ton TL; Shaghafi MB; Hu H; Lehoux I; To N; Young WB; Green MJ
Bioorg Med Chem Lett; 2011 Jan; 21(1):82-7. PubMed ID: 21145235
[TBL] [Abstract][Full Text] [Related]
11. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase.
Kukolj G; McGibbon GA; McKercher G; Marquis M; Lefèbvre S; Thauvette L; Gauthier J; Goulet S; Poupart MA; Beaulieu PL
J Biol Chem; 2005 Nov; 280(47):39260-7. PubMed ID: 16188890
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infections.
Beaulieu PL; Tsantrizos YS
Curr Opin Investig Drugs; 2004 Aug; 5(8):838-50. PubMed ID: 15600240
[TBL] [Abstract][Full Text] [Related]
13. Multiple e-pharmacophore modeling, 3D-QSAR, and high-throughput virtual screening of hepatitis C virus NS5B polymerase inhibitors.
Therese PJ; Manvar D; Kondepudi S; Battu MB; Sriram D; Basu A; Yogeeswari P; Kaushik-Basu N
J Chem Inf Model; 2014 Feb; 54(2):539-52. PubMed ID: 24460140
[TBL] [Abstract][Full Text] [Related]
14. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and preliminary SAR of benzimidazole derivatives.
Beaulieu PL; Bös M; Bousquet Y; Fazal G; Gauthier J; Gillard J; Goulet S; LaPlante S; Poupart MA; Lefebvre S; McKercher G; Pellerin C; Austel V; Kukolj G
Bioorg Med Chem Lett; 2004 Jan; 14(1):119-24. PubMed ID: 14684311
[TBL] [Abstract][Full Text] [Related]
15. Non-nucleoside inhibitors of the hepatitis C virus NS5B RNA-dependant RNA polymerase: 2-aryl-3-heteroaryl-1,3-thiazolidin-4-one derivatives.
Rawal RK; Katti SB; Kaushik-Basu N; Arora P; Pan Z
Bioorg Med Chem Lett; 2008 Dec; 18(23):6110-4. PubMed ID: 18947995
[TBL] [Abstract][Full Text] [Related]
16. Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition.
Biswal BK; Wang M; Cherney MM; Chan L; Yannopoulos CG; Bilimoria D; Bedard J; James MN
J Mol Biol; 2006 Aug; 361(1):33-45. PubMed ID: 16828488
[TBL] [Abstract][Full Text] [Related]
17. Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients.
Troke PJ; Lewis M; Simpson P; Gore K; Hammond J; Craig C; Westby M
Antimicrob Agents Chemother; 2012 Mar; 56(3):1331-41. PubMed ID: 22203605
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of inhibition for BMS-791325, a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase.
Rigat KL; Lu H; Wang YK; Argyrou A; Fanslau C; Beno B; Wang Y; Marcinkeviciene J; Ding M; Gentles RG; Gao M; Abell LM; Roberts SB
J Biol Chem; 2014 Nov; 289(48):33456-68. PubMed ID: 25301950
[TBL] [Abstract][Full Text] [Related]
19. Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus.
Hang JQ; Yang Y; Harris SF; Leveque V; Whittington HJ; Rajyaguru S; Ao-Ieong G; McCown MF; Wong A; Giannetti AM; Le Pogam S; Talamás F; Cammack N; Nájera I; Klumpp K
J Biol Chem; 2009 Jun; 284(23):15517-29. PubMed ID: 19246450
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in discovery and development of promising therapeutics against hepatitis C virus NS5B RNA-dependent RNA polymerase.
Wu JZ; Yao N; Walker M; Hong Z
Mini Rev Med Chem; 2005 Dec; 5(12):1103-12. PubMed ID: 16375756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
